EFFECTS OF SAM IN PATIENTS WITH ALCOHOLIC LIVER DISEASE

SAM 对酒精性肝病患者的影响

基本信息

项目摘要

DESCRIPTION (provided by applicant): Prior evidence from controlled animal studies has established the association of abnormal hepatic methionine metabolism and the development of alcoholic liver disease (ALD), and two clinical studies suggest that S-adenosylmethionine (SAM) may be efficacious in promoting anti-oxidant defense and survival in patients with moderately severe disease. Liver SAM is deficient in animal models of ALD, regulates several methionine cycle pathways, and up-regulates the synthesis of glutathione. The overall hypothesis of the proposed research is that the severity of ALD correlates with abnormal hepatic methionine metabolism and is improved by SAM intervention, and the overall objective is to define the metabolic rationale and short term efficacy of the clinical use of SAM in the treatment of ALD. Specific Aim I is to contrast the profiles of SAM, its product S-adenosylhomocysteine (SAH), and other methionine metabolites in liver biopsies and blood samples from 40 stable ALD patients contrasting with findings in 40 non-alcoholic non-liver disease patient controls and in blood samples from 20 healthy subjects. These data will be used to determine relationships between liver and blood SAM, SAH, and other metabolite levels and to define the effect of ALD and its severity on methionine metabolites. Specific Aim II is to demonstrate the metabolic and clinical efficacy of SAM treatment in the same 40 ALD patients who will be randomized to receive SAM or placebo in three daily doses over 6 mo. Blood samples at intervals will be used for measurements of SAM, SAH and other metabolites and markers of liver oxidative injury and function. Histopathology will be assessed by a computerized grading system in liver biopsies obtained before and after treatment. These data will be used to determine the effects of SAM intervention on methionine metabolism and to establish a rationale for its use according to quantitative changes in oxidative injury, liver function, and histopathology. By confirming the relationship of abnormal methionine metabolism to clinical, biochemical, and pathologic disease severity, the study will establish a metabolic basis for determining the efficacy of SAM intervention in ALD.
描述(由申请人提供):来自对照动物研究的先前证据已经建立了肝脏蛋氨酸代谢异常与酒精性肝病(ALD)发展的关联,两项临床研究表明s -腺苷蛋氨酸(SAM)可能有效促进中重度疾病患者的抗氧化防御和生存。肝脏SAM在ALD动物模型中缺乏,调节几种蛋氨酸循环途径,上调谷胱甘肽的合成。本研究的总体假设是ALD的严重程度与肝脏蛋氨酸代谢异常相关,并通过SAM干预得到改善,总体目标是明确临床使用SAM治疗ALD的代谢原理和短期疗效。具体目的1是对比40例稳定型ALD患者肝活检和血液样本中SAM、其产物s -腺苷型同型半胱氨酸(SAH)和其他蛋氨酸代谢物的特征,并与40例非酒精性非肝病患者对照和20例健康受试者血液样本中的发现进行对比。这些数据将用于确定

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHARLES HOPKINSON HALSTED其他文献

CHARLES HOPKINSON HALSTED的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHARLES HOPKINSON HALSTED', 18)}}的其他基金

Epigenetic regulation of alcoholic steatohepatitis in a mouse model
小鼠模型中酒精性脂肪性肝炎的表观遗传调控
  • 批准号:
    8174622
  • 财政年份:
    2011
  • 资助金额:
    $ 30.1万
  • 项目类别:
Epigenetic regulation of alcoholic steatohepatitis in a mouse model
小鼠模型中酒精性脂肪性肝炎的表观遗传调控
  • 批准号:
    8322621
  • 财政年份:
    2011
  • 资助金额:
    $ 30.1万
  • 项目类别:
Folic Acid Vitamin B12 and One Carbon Metabolism
叶酸维生素 B12 和一碳代谢
  • 批准号:
    8004231
  • 财政年份:
    2010
  • 资助金额:
    $ 30.1万
  • 项目类别:
EFFECTS OF SAM IN PATIENTS WITH ALCOHOLIC LIVER DISEASE
SAM 对酒精性肝病患者的影响
  • 批准号:
    7014538
  • 财政年份:
    2005
  • 资助金额:
    $ 30.1万
  • 项目类别:
EFFECTS OF SAM IN PATIENTS WITH ALCOHOLIC LIVER DISEASE
SAM 对酒精性肝病患者的影响
  • 批准号:
    7194276
  • 财政年份:
    2005
  • 资助金额:
    $ 30.1万
  • 项目类别:
EFFECTS OF SAM IN PATIENTS WITH ALCOHOLIC LIVER DISEASE
SAM 对酒精性肝病患者的影响
  • 批准号:
    6975653
  • 财政年份:
    2004
  • 资助金额:
    $ 30.1万
  • 项目类别:
SAMe and Folate Deficiency in Alcoholic Mircropigs
酒精微型猪的 SAMe 和叶酸缺乏症
  • 批准号:
    6685034
  • 财政年份:
    2003
  • 资助金额:
    $ 30.1万
  • 项目类别:
SAMe and Folate Deficiency in Alcoholic Mircropigs
酒精微型猪的 SAMe 和叶酸缺乏症
  • 批准号:
    6785258
  • 财政年份:
    2003
  • 资助金额:
    $ 30.1万
  • 项目类别:
SAMe and Folate Deficiency in Alcoholic Mircropigs
酒精微型猪的 SAMe 和叶酸缺乏症
  • 批准号:
    6924648
  • 财政年份:
    2003
  • 资助金额:
    $ 30.1万
  • 项目类别:
SAMe and Folate Deficiency in Alcoholic Mircropigs
酒精微型猪的 SAMe 和叶酸缺乏症
  • 批准号:
    7106391
  • 财政年份:
    2003
  • 资助金额:
    $ 30.1万
  • 项目类别:

相似海外基金

GPR35: mechanisms of action and agonism as a potential therapeutic strategy for non-alcoholic fatty liver diseases
GPR35:作为非酒精性脂肪肝疾病潜在治疗策略的作用和激动机制
  • 批准号:
    MR/X008827/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.1万
  • 项目类别:
    Research Grant
Perfluoroalkyl substances and non-alcoholic fatty liver disease in children: Leveraging magnetic resonance imaging to unravel potential mechanisms and exposure mixture effects
全氟烷基物质与儿童非酒精性脂肪肝:利用磁共振成像揭示潜在机制和暴露混合物效应
  • 批准号:
    10646759
  • 财政年份:
    2023
  • 资助金额:
    $ 30.1万
  • 项目类别:
Development of Early Diagnostic Markers for Non-Alcoholic Fatty Liver Disease (NAFLD) and Investigation of Inflammatory Mechanisms of NAFLD
非酒精性脂肪性肝病(NAFLD)早期诊断标志物的开发及NAFLD炎症机制的研究
  • 批准号:
    23K07466
  • 财政年份:
    2023
  • 资助金额:
    $ 30.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Bacteriotherapy to treat non-alcoholic fatty liver disease
细菌疗法治疗非酒精性脂肪肝
  • 批准号:
    2893992
  • 财政年份:
    2023
  • 资助金额:
    $ 30.1万
  • 项目类别:
    Studentship
The Gut-Liver Axis in HIV-Related Non-Alcoholic Fatty Liver Disease
HIV 相关非酒精性脂肪肝中的肠肝轴
  • 批准号:
    10762284
  • 财政年份:
    2023
  • 资助金额:
    $ 30.1万
  • 项目类别:
Investigating folliculin as a regulator of VLDL-TG secretion in non-alcoholic fatty liver disease and steatohepatitis
研究卵泡素作为非酒精性脂肪肝和脂肪性肝炎中 VLDL-TG 分​​泌的调节剂
  • 批准号:
    10679361
  • 财政年份:
    2023
  • 资助金额:
    $ 30.1万
  • 项目类别:
Epidemiology of diet, metabolism and non-alcoholic fatty liver disease in Hispanic/Latino adults
西班牙裔/拉丁裔成人饮食、代谢和非酒精性脂肪肝的流行病学
  • 批准号:
    10735454
  • 财政年份:
    2023
  • 资助金额:
    $ 30.1万
  • 项目类别:
Elucidation of molecular mechanisms of SBP1-based regulation of non-alcoholic fatty liver development/progression
阐明基于 SBP1 调节非酒精性脂肪肝发生/进展的分子机制
  • 批准号:
    23K10862
  • 财政年份:
    2023
  • 资助金额:
    $ 30.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Them1 Inhibitors for the Management of Non-Alcoholic Fatty Liver Disease
Them1 治疗非酒精性脂肪肝的抑制剂
  • 批准号:
    10666090
  • 财政年份:
    2023
  • 资助金额:
    $ 30.1万
  • 项目类别:
Uncovering the role of GPR75 as an activator of fatty acid transporters in non-alcoholic fatty liver disease (NAFLD)
揭示 GPR75 作为脂肪酸转运蛋白激活剂在非酒精性脂肪性肝病 (NAFLD) 中的作用
  • 批准号:
    10666762
  • 财政年份:
    2023
  • 资助金额:
    $ 30.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了